May enhance the sedative effects of alcohol, and the effects of barbiturates and other CNS depressants. Drug reduces the antihypertensive effect of guanethidine. Tricyclic antidepressants and neuroleptics mutually inhibit the metabolism of each other. Zuclopenthixol may reduce the effect of levodopa and the effect of adrenergic drugs. Concurrent use of metoclopramide and piperazine with zuclopenthixol increases the risk of extrapyrimidal symptoms.

Drowsiness, extrapyriamidal symptoms may occur, especially during the early phase of treatment. In most cases these side effects can be satisfactorily controlled by reduction of dosage and/or antiparkinson drugs. Like other conventional antipsychotics, in long term treatment tardive dyskinesia may occur occasionally.

Hypersensitivity, circulatory collapse, CNS depression(acute alcohol, barbiturates and opiate intoxifications) comatose states, blood dyscrasias, and phaeochromotytoma.

Special precautions :

Caution to be excercised initially, until the individual's recation to treatment is known. Ability to drive a car may be affected.

Zuclopenthixol should preferably not given during pregnancy. Possiblity of neuroleptic malignant syndrome exists.

Risk is greater with the more potent agents. Patients with pre-existing organic brain syndrome, mental retardation, and opiate or alcohol abuse are over-represented among fatal cases.

To be used with caution on patients with advanced hepatic and cardiovascular disease. The drug may modify insulin and glucose responses calling for sdjustment of antidiabetic therapy in diabetic patients Use in children not recommended.,

Psychosis, schizophrenia Zuclopenthixol acetate

Dosage-

Dose range normally be 50- 150mg IM. Repeat if necessary with an interval of 2-3 days. Zuclopenthixol deconate

Maintenance dose range 200- 400mg every second to fourth week. Few pateints may need higher dose. Zuclopenthixol hydrochloride

Oral treatment- Maintenance dose 2 -50mg daily.

1. Ability to drive a car may be affected.

2. Zuclopenthixol should preferably not given during pregnancy.

3.Use with caution on patients with advanced hepatic and cardiovascular disease.

4. The drug may modify insulin and glucose responses calling for sdjustment of antidiabetic therapy in diabetic patients Zuclopenthixol should preferably not given during ptregnancy.

5.Use with caution on patients with advanced hepatic and ca

Pharmacology:

Zuclopenthixol has a high affinity for Dopamine D2 receptors- around 80% occupancy in humans,at therapeutic doses which may provide control to positive symptoms of schizophrenia while being around the threshold for inducing extrapyrimidal symptoms. However unlike Haloperidol and most other typical antipsychotics, zuclopenthixol also has 40-50% serotin 5-HT 2 receptor occupancy, which may contribute to the reduction of the risk of extrapyrimidal symptoms The weak antagonistic activity at histamine H2 receptors gives rise to the intial sedative effect of zuclophenthixol

Pregnancy Zuclopenthixol should preferably not given during pregnancy. Children Use not recommended